Last reviewed · How we verify
NCT06364839
Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases
trial in Hepatocellular Carcinoma, Non-cirrhotic Liver in 1 participant. Completed in 25 March 2024.
23 March 2024
Quick facts
| Lead sponsor | Xiao Xu |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 20 February 2024 |
| Primary completion | 23 March 2024 |
| Estimated completion | 25 March 2024 |
| Sites | 1 location across China |
Conditions studied
- Hepatocellular Carcinoma, Non-cirrhotic Liver — all drugs for Hepatocellular Carcinoma, Non-cirrhotic Liver →
Sponsor
Xiao Xu
Who can join
Eligibility, any sex, with Hepatocellular Carcinoma, Non-cirrhotic Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Majority of liver transplantation (LT) recipients for hepatocellular carcinoma (HCC) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis. Here we aim to investigate the prognosis of non-cirrhosis HCC recipients, expecting to provide theoretical basis for further improvement of these patients. Methods: This retrospective study analyze outcomes between adult HCC recipients arising in non-cirrhotic and cirrhotic liver from two national databases (CLTR and UNOS, January 2015 to December 2020). Based on important variables, 1:2 and 1:1 propensity score matching (PSM) were performed respectively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06364839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Xiao Xu trials
Trials by the same sponsor.
- NCT06420791 — The Dual Impact of Cirrhosis on Transplantation for Hepatocellular Carcinoma：a Two-center Retrospective Cohort Study in · completed
- NCT06564103 — Stratification for F-L Therapy After LT · completed
- NCT06787534 — The Favorable Impact of HBcAb Positive Grafts on Liver Transplantation for HBV-related HCC · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06364839 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiao Xu
- Last refreshed: 15 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06364839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing